AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2026)
AbCellera Biologics' (ABCL) quarterly Return on Capital Employed came in at 16.5% in Q1 2026, up 876.0% YoY from 1.69% in Q1 2025, and up 1.8% on a QoQ basis from 16.8% in Q4 2025.
AbCellera Biologics (ABCL) Return on Capital Employed (2021 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 6 years of Return on Capital Employed data on file, last reported at 16.5% in Q1 2026.
- Quarterly Return on Capital Employed rose 876.0% year-over-year to 16.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.5% (up 876.0% YoY) and the FY2025 annual result came in at 16.77%, up 658.0% from the prior year.
- Return on Capital Employed climbed to 16.5% in Q1 2026, from 16.8% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 22.89% in Q3 2022 to a low of 25.26% in Q1 2025.
- A 5-year average of 8.79% and a median of 16.58% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 3766 bps — and 2026, when it surged 876 bps.
- Tracing ABCL's Return on Capital Employed over 5 years: stood at 15.16% in 2022, then sank by 213 bps to 17.17% in 2023, then plunged by 41 bps to 24.21% in 2024, then surged by 31 bps to 16.8% in 2025, then grew by 2 bps to 16.5% in 2026.
- The last three Return on Capital Employed figures came in at 16.5% (Q1 2026), 16.8% (Q4 2025), and 19.94% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | -17.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.95% |
| Mar 31, 2026 | -16.50% |
| Dec 31, 2025 | -16.80% |
| Sep 30, 2025 | -19.94% |
| Jun 30, 2025 | -21.34% |
| Mar 31, 2025 | -25.26% |
| Dec 31, 2024 | -24.21% |
| Sep 30, 2024 | -23.28% |
| Jun 30, 2024 | -19.69% |
| Mar 31, 2024 | -16.58% |
| Dec 31, 2023 | -17.17% |
| Sep 30, 2023 | -14.77% |
| Jun 30, 2023 | -8.32% |
| Mar 31, 2023 | -5.13% |
| Dec 31, 2022 | 15.16% |
| Sep 30, 2022 | 22.89% |
| Jun 30, 2022 | 19.68% |
| Mar 31, 2022 | 21.85% |
| Dec 31, 2021 | 18.18% |
| Sep 30, 2021 | 25.50% |